Health and Healthcare Systems

How to restore data privacy after the coronavirus pandemic

A man wearing a protective mask walks under surveillance cameras in Shanghai, China, as the country is hit by a novel coronavirus outbreak, at the Pudong financial district in Shanghai, China February 28, 2020. REUTERS/Aly Song - RC2L9F94G6TH

Surveillance has become an essential tool in the fight against coronavirus. Image: REUTERS/Aly Song

Samantha Stein
  • Government surveillance to halt COVID-19 has sparked privacy concerns.
  • Companies storing sensitive data will be restricted by data privacy regulations, such as GDPR.
  • Privacy-Enhancing Technology helps companies use data without revealing confidential information.

As scientists around the world work tirelessly to develop a viable vaccine, coordinated data-sharing has become an essential tool in the ongoing fight against coronavirus. In an effort to establish effective public health strategies and protocols for curtailing the spread of COVID-19, mass data collection methods are already being put to use.

Have you read?

Naturally, any type of sweeping government-sanctioned surveillance programme, however well-intentioned, raises serious questions: how is our sensitive data being used? Who has access to it? How vulnerable is our data to leaks and hacks? How could it be exploited by private companies in the future? And, of course, is there a way to mitigate the risk of privacy breaches?

These are important questions that will most certainly resurface – even if we’re too preoccupied to think about them today – once panic ebbs and calm has been restored in the post-coronavirus era.

Keeping close tabs on the health and location data of local populations may, in fact, be the key to an effective containment strategy. For example, real-time data about the geographic distribution and health status of both the quarantined and infected patients reveals critical insights about the effectiveness of preventive health measures. Our personal data is currently being collected, used and shared in a variety of ways:

  • Mobile location data is providing governments with advanced tracking capabilities to help authorities enforce quarantines.
  • Facial recognition technology linked with biometric databases is being integrated with digital thermometers to help capture the identity of individuals with a fever.
  • Open-source applications like Nextstrain are using Gisaid, a platform for sharing genomic data, to help researchers track and study the evolution of coronavirus.
Total confirmed cases and total deaths from coronavirus worldwide, as of March 30.
Total confirmed cases and total deaths from coronavirus worldwide, as of March 30. Image: Worldometers

During an extraordinary crisis, many governments are willing to overlook privacy implications in an effort to save lives. However, the sensitive data that’s being collected is not exclusive to public health organizations and governments. In the United States, the government is openly working with Verily, a Google sister company, to offer online screening tests that require users to have a Google account. Sensitive data is also being accessed by surveillance technology companies and mobile app developers. Users of the Corona 100m app, for example, can see the date that a coronavirus patient was infected, along with his or her nationality, gender, age and the locations they visited.

Discover

What is the World Economic Forum doing about the coronavirus outbreak?

Under ordinary circumstances, sensitive patient-linked medical records can and should be kept private. Exposing them to private companies, even in the interest of public health, is a source of concern because these records hold significant commercial value. They could, for instance, provide advertising agencies with valuable targeting data for healthcare and pharmaceutical companies. They could also help inform decision-making by health insurers seeking to verify medical histories when processing new policies and claims. Databases that contain identities linked with mobile location data also carry a price tag, especially for consumer markets.

Companies seeking to store sensitive data of any kind, and perhaps leverage it for future commercial gain, will be restricted by data privacy regulations such as the EU’s General Data Protection Regulation (GDPR) and the California Consumer Privacy Act (CCPA). However, to fully ensure regulatory compliance and protect data – an exponentially valuable business asset – enterprises must embrace the latest innovations in Privacy-Enhancing Technology (PET). This new category of privacy technology, as highlighted by the World Economic Forum, enables businesses to leverage insights derived from third-party private data without revealing confidential information that cannot and should not be shared for ethical, legal or business reasons.

Implementing PET, as discussed in US Senator Kirsten Gillibrand’s recently proposed Data Protection Act, should be a critical priority for the business community. Fortunately for enterprises, advanced cryptographic techniques based on PET are already in use. They have been rigorously tried and tested by the global academic community, and industry leaders are actively involved in PET standardization efforts like ZKProof to facilitate wider adoption. If implemented properly, PET can empower, rather than constrain, companies. It can help them safely leverage third-party data and stay competitive, without putting user privacy or confidential business data at risk.

In these uncertain times, as our governments explore data-driven solutions to curb a global health pandemic, we must consider how our data will be handled in the aftermath of the coronavirus. This crisis will eventually pass and, as new data challenges arise, privacy technologies must become the standard for enterprises and governments alike, to ensure we are best equipped to facilitate wide-scale privacy-enabled data collaboration before the next crisis unfolds.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Stay up to date:

Data Science

Share:
The Big Picture
Explore and monitor how Data Science is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

The key health achievements of COP29, and other top health stories

Shyam Bishen

November 20, 2024

How equitable access to medicines can drive sustainable returns for investors

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2024 World Economic Forum